Literature DB >> 19614971

Changes in serum cytokine levels during plasmapheresis in patients with myasthenia gravis.

J-H Yeh1, S-H Wang, P-J Chien, C-M Shih, H-C Chiu.   

Abstract

BACKGROUND: The effect of plasmapheresis on cytokine levels in patients with myasthenia gravis (MG) has not been well established.
METHODS: Cytokine levels were measured in 19 patients with MG before and after treatment with one course of double-filtration plasmapheresis (DFP). The control group comprised 6 age- and sex-matched healthy volunteers.
RESULTS: At baseline, patients with MG had higher levels of IL-10 than normal controls. The levels of IL-2, IL-4, IL-5, and tumor necrosis factor-alpha were almost undetectable in MG patients. After a single session of DFP treatment, IL-10 levels were significantly increased. After three sessions, IL-10 levels were still higher than those at baseline. Elevated IL-10 level was significantly associated with use of immunosuppressant drugs, thymectomy, and good response to DFP treatment.
CONCLUSIONS: Interleukin-10 might play a crucial role in the pathogenesis and perpetuation of MG.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19614971     DOI: 10.1111/j.1468-1331.2009.02729.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  14 in total

1.  Can plasma exchange therapy induce regulatory T lymphocytes in multiple sclerosis patients?

Authors:  A Jamshidian; M Gharagozloo
Journal:  Clin Exp Immunol       Date:  2012-04       Impact factor: 4.330

2.  Plasmapheresis and immunoadsorption in patients with steroid refractory multiple sclerosis relapses.

Authors:  Simon Faissner; Johanna Nikolayczik; Andrew Chan; Kerstin Hellwig; Ralf Gold; Min-Suk Yoon; Aiden Haghikia
Journal:  J Neurol       Date:  2016-04-02       Impact factor: 4.849

3.  Th1 - CD11c+ B Cell Axis Associated with Response to Plasmapheresis in Multiple Sclerosis.

Authors:  Kimitoshi Kimura; Youwei Lin; Hiromi Yamaguchi; Wakiro Sato; Daiki Takewaki; Misako Minote; Yoshimitsu Doi; Tomoko Okamoto; Ryosuke Takahashi; Takayuki Kondo; Takashi Yamamura
Journal:  Ann Neurol       Date:  2021-10       Impact factor: 11.274

Review 4.  Roles of cytokines and T cells in the pathogenesis of myasthenia gravis.

Authors:  A Uzawa; S Kuwabara; S Suzuki; T Imai; H Murai; Y Ozawa; M Yasuda; Y Nagane; K Utsugisawa
Journal:  Clin Exp Immunol       Date:  2020-12-03       Impact factor: 5.732

5.  Differential Cytokine Changes in Patients with Myasthenia Gravis with Antibodies against AChR and MuSK.

Authors:  Vuslat Yilmaz; Piraye Oflazer; Fikret Aysal; Hacer Durmus; Kostas Poulas; Sibel P Yentur; Yesim Gulsen-Parman; Socrates Tzartos; Alexander Marx; Erdem Tuzun; Feza Deymeer; Güher Saruhan-Direskeneli
Journal:  PLoS One       Date:  2015-04-20       Impact factor: 3.240

Review 6.  Application of Plasma Exchange in Steroid-Responsive Encephalopathy.

Authors:  Yuting Jiang; Xin Tian; Yixue Gu; Feng Li; Xuefeng Wang
Journal:  Front Immunol       Date:  2019-02-27       Impact factor: 7.561

7.  Efficacy and safety of double-filtration plasmapheresis treatment of myasthenia gravis: A systematic review and meta-analysis.

Authors:  Chaoying Liu; Peng Liu; Mei Ma; Hongxia Yang; Guoyan Qi
Journal:  Medicine (Baltimore)       Date:  2021-04-30       Impact factor: 1.817

8.  Serum proteomic, peptidomic and metabolomic profiles in myasthenia gravis patients during treatment with Qiangji Jianli Fang.

Authors:  Chunmei Wang; Yonghai Lu; Zhixi Chen; Xiaobin Liu; Huangquan Lin; Hui Zhao; Jinyan Chen; Yiuwa Kwan; Saiming Ngai
Journal:  Chin Med       Date:  2012-07-28       Impact factor: 5.455

9.  AMBAR, an Encouraging Alzheimer's Trial That Raises Questions.

Authors:  David A Loeffler
Journal:  Front Neurol       Date:  2020-05-29       Impact factor: 4.003

Review 10.  Current Treatment of Myasthenia Gravis.

Authors:  Mohammed K Alhaidar; Sumayyah Abumurad; Betty Soliven; Kourosh Rezania
Journal:  J Clin Med       Date:  2022-03-14       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.